The impact of pharmacokinetic gene profiles across human cancers

BMC Cancer

Table 1 Number of samples available and covariates considered for each cancer type. Column names designate covariates with a bullet indicating inclusion of that covariate in survival models

	#T	#E	#N	TSS^a	Age	Sex	Stage	Grade	LI^b	Smoke status^c	Tumor specific^d
GBM	394	154	0	●	●	●					●
OV	573	262	0	●	●		●	●	●		●
BRCA	905	817	104	●	●		●				●
UCEC	473	333	5	●	●		●	●
KIRC	505	470	65	●	●	●	●	●
COAD	424	192	0	●	●	●	●		●		●
READ	168	71	0	●	●	●	●		●		●
BLCA	139	96	13	●	●	●	●			●
LUAD	447	353	55	●	●	●				●
LUSC	404	220	16	●	●	●				●
HNSC	409	303	37	●	●	●	●	●		●

#T, total number of tumor samples
#E, number of tumor
#N, number of tissue-matched normal samples
^aRandom intercept terms were included for Tissue Source Site
^bLymphatic Invasion; coded as “present” or not
^cCigarette smoking status
^dMeasures used in only one cancer type. GBM: Radiation dosage. OV: tumor residual disease. BRCA: menopause status, margin status. COAD and READ: history of colon polyps

ISSN: 1471-2407